top
Please input keywords
Fully human antibody discovery and development

Based on our proprietary fully human antibody mice RenMice (RenMab、RenLite、RenNano), we have trained talents and have established a fully integrated one-stop solution from target validation to clinical studies. Taking advantage of cutting-edge antibody discovery technologies like the Beacon Opto-Select single B cell antibody discovery technology, within a much shortened timeline, we generate more antibodies with much higher diversity against a variety of targets including difficult targets like GPCRs. Utilizing our industry-leading genome targeting capability, we break immune tolerance by target gene knockout and generate antibodies with cross-species binding specificity. Cross-species binding specificity enables us to quickly screen for preclinical candidates of interest in wild type laboratory mice and to further validate the candidates in larger animals like companion pets for better translational success. Antibody engineering, developability assessment, cell line and process development are built in to ensure a smooth transition from early discovery to development stage. We envision to finish early discovery of over 1400 targets involved in human diseases within three years to address the unmet needs and to benefits the patients in need.


I、Platform Capabilities

1. RenMab mouse: 


RenMab mice carry fully human antibody variable domains, eliminating the need of antibody humanization. Natural in vivo selection and affinity optimization by the murine immune system generate antibodies with better physic-chemical propertiesand good drug like properties.


2. RenLite mouse: 


The common light chain antibody mice RenLite are better poised for the development of monovalent bispecifics. With a shared light chain, common technical challenges in bispecific antibody development like heavy-light chains mis-pairing and very poor developability issues are properly addressed.


3. RenNano mouse: 


RenNano mice provide very innovative solutions for single domain antibody discovery. Due to a much smaller size, single domain antibodies demonstrated better tissue penetration and the capability to cross blood-brain barrier.


4.Versatile antibody discovery toolkit


We deploy a versatile antibody discovery toolkit for fast antibody discovery with accerelated timeline, including Beacon Opto-Select-based single plasma cell antibody discovery, FACS-based single B cell sorting antibody discovery and in vitro display technologies like phage display.


5.Difficult targets: 


For difficult targets like GPCRs and ion channels, we build our success upon innovative antigen design, proprietary immunization strategies, fit-for-purpose antibody discovery and very comprehensive cell-based functional assays.


6.Cross-species binding specificity:


We break immune tolerance by target gene knockout in RenMab/RenLite/RenNano mice. Antibodies with cross-species binding specificity will be screened for in vivo functions in wild-type laboratory mice and be further validated in larger animals like companion pets for better translational success.


7.Antibody analytics and developability assessment:


Comprehensive antibody analytics and developability assays will be performed to nominate antibody hits with better development success rate.


8.Antibody engineering:


AI-assisted antibody engineering capability for fit-for-purpose engineering of antibodies like affinity modulation, liability engineering, developability optimization and effector function engineering etc.


9.Cell line development:


Industry-leading stable cell line development capability for higher yield and shortened timeline.


II、Technology Classification and Designation

Antibody Discovery


Beacon OptoSelect-based single plasma cell antibody discovery



Physicochemical analytics



SEC-HPLC monomeric analysis



FACS-based single B cell antibody discovery



CEX-HPLC heterogeneity and charge variants



Phage display selection of immune library



Intact molecular weight



Hybridoma



Peptide mapping


In vitro functional analysis

EC50——ELISA/FACS


Post translational modification analysis


IC50——ELISA/FACS


N/C heterogeneity analysis (mass spec)



Binding kinetic analysis



Monosaccharide mapping




Isoelectric point



Epitope binning analysis



CE-SDS



ADCC/ADCP/CDC effector function analysis



Melting temperature 



Internalization



Thermostability analysis



Reporter cell-based assays



Hydrophobicity by HIC-HPLC



FcγRs binding kinetics



Disulfide bond analysis



C1q binding kinetics